Sub-Total: $0.00
New Era in the Lipid Lowering Treatment with PCSK9 Inhibitors (Evolocumab and Alirocumab) in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia
Complimentary
Related products
-
New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases
Read more -
Novel Therapies for Chronic Rhinosinusitis with Nasal Polyps
Read more -
New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
Read more -
Glaucoma: Sustained-release Drug Delivery System, Topical Agents, and Emerging 3D Visualization Technologies
Read more
